These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 27993569)

  • 1. A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study.
    Scott JG; Berglund A; Schell MJ; Mihaylov I; Fulp WJ; Yue B; Welsh E; Caudell JJ; Ahmed K; Strom TS; Mellon E; Venkat P; Johnstone P; Foekens J; Lee J; Moros E; Dalton WS; Eschrich SA; McLeod H; Harrison LB; Torres-Roca JF
    Lancet Oncol; 2017 Feb; 18(2):202-211. PubMed ID: 27993569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of a genome-based model for adjusting radiotherapy dose (GARD) in patients with locally advanced rectal cancer.
    Xia H; Li Z; Lin Y; Lin Y; Zeng L; Xu B; Yao Q; Zheng R
    Sci Rep; 2024 Sep; 14(1):21572. PubMed ID: 39284851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utilizing the genomically adjusted radiation dose (GARD) to personalize adjuvant radiotherapy in triple negative breast cancer management.
    Ahmed KA; Liveringhouse CL; Mills MN; Figura NB; Grass GD; Washington IR; Harris EE; Czerniecki BJ; Blumencranz PW; Eschrich SA; Scott JG; Diaz R; Torres-Roca JF
    EBioMedicine; 2019 Sep; 47():163-169. PubMed ID: 31416721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pan-cancer prediction of radiotherapy benefit using genomic-adjusted radiation dose (GARD): a cohort-based pooled analysis.
    Scott JG; Sedor G; Ellsworth P; Scarborough JA; Ahmed KA; Oliver DE; Eschrich SA; Kattan MW; Torres-Roca JF
    Lancet Oncol; 2021 Sep; 22(9):1221-1229. PubMed ID: 34363761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiosensitivity of Lung Metastases by Primary Histology and Implications for Stereotactic Body Radiation Therapy Using the Genomically Adjusted Radiation Dose.
    Ahmed KA; Scott JG; Arrington JA; Naghavi AO; Grass GD; Perez BA; Caudell JJ; Berglund AE; Welsh EA; Eschrich SA; Dilling TJ; Torres-Roca JF
    J Thorac Oncol; 2018 Aug; 13(8):1121-1127. PubMed ID: 29733909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using the genomic adjusted radiation dose (GARD) to personalize the radiation dose in nasopharyngeal cancer.
    Chiang CL; Chan KSK; Li H; Ng WT; Chow JCH; Choi HCW; Lam KO; Lee VHF; Ngan RKC; Lee AWM; Eschrich SA; Torres-Roca JF; Wong JWH
    Radiother Oncol; 2024 Jul; 196():110287. PubMed ID: 38636709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A clinicogenomic model including GARD predicts outcome for radiation treated patients with HPV+ oropharyngeal squamous cell carcinoma.
    Ho E; De Cecco L; Cavalieri S; Sedor G; Hoebers F; Brakenhoff RH; Scheckenbach K; Poli T; Yang K; Scarborough JA; Campbell S; Koyfman S; Eschrich SA; Caudell JJ; Kattan MW; Licitra L; Torres-Roca JF; Scott JG
    medRxiv; 2023 Sep; ():. PubMed ID: 37745365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular signature of response to preoperative radiotherapy in locally advanced breast cancer.
    Tanić M; Krivokuća A; Čavić M; Mladenović J; Plesinac Karapandžić V; Beck S; Radulović S; Susnjar S; Janković R
    Radiat Oncol; 2018 Oct; 13(1):193. PubMed ID: 30285791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic analysis of exceptional responders to radiotherapy reveals somatic mutations in ATM.
    Ma J; Setton J; Morris L; Albornoz PB; Barker C; Lok BH; Sherman E; Katabi N; Beal K; Ganly I; Powell SN; Lee N; Chan TA; Riaz N
    Oncotarget; 2017 Feb; 8(6):10312-10323. PubMed ID: 28055970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of a radiosensitivity molecular signature in breast cancer.
    Eschrich SA; Fulp WJ; Pawitan Y; Foekens JA; Smid M; Martens JW; Echevarria M; Kamath V; Lee JH; Harris EE; Bergh J; Torres-Roca JF
    Clin Cancer Res; 2012 Sep; 18(18):5134-43. PubMed ID: 22832933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
    Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
    Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring breast and prostate cancer RNA-seq derived radiosensitivity with the Genomic Adjusted Radiation Dose (GARD) model.
    Nolan B; O'Sullivan B; Golden A
    Clin Transl Radiat Oncol; 2022 Sep; 36():127-131. PubMed ID: 36017133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour radiosensitivity is associated with immune activation in solid tumours.
    Strom T; Harrison LB; Giuliano AR; Schell MJ; Eschrich SA; Berglund A; Fulp W; Thapa R; Coppola D; Kim S; Frakes J; Foekens J; Mulé JJ; Torres-Roca JF
    Eur J Cancer; 2017 Oct; 84():304-314. PubMed ID: 28863385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
    Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
    Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The radiosensitivity index predicts for overall survival in glioblastoma.
    Ahmed KA; Chinnaiyan P; Fulp WJ; Eschrich S; Torres-Roca JF; Caudell JJ
    Oncotarget; 2015 Oct; 6(33):34414-22. PubMed ID: 26451615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toward patient-specific, biologically optimized radiation therapy plans for the treatment of glioblastoma.
    Corwin D; Holdsworth C; Rockne RC; Trister AD; Mrugala MM; Rockhill JK; Stewart RD; Phillips M; Swanson KR
    PLoS One; 2013; 8(11):e79115. PubMed ID: 24265748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiosensitivity index predicts for survival with adjuvant radiation in resectable pancreatic cancer.
    Strom T; Hoffe SE; Fulp W; Frakes J; Coppola D; Springett GM; Malafa MP; Harris CL; Eschrich SA; Torres-Roca JF; Shridhar R
    Radiother Oncol; 2015 Oct; 117(1):159-64. PubMed ID: 26235848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.
    Malmström A; Grønberg BH; Marosi C; Stupp R; Frappaz D; Schultz H; Abacioglu U; Tavelin B; Lhermitte B; Hegi ME; Rosell J; Henriksson R;
    Lancet Oncol; 2012 Sep; 13(9):916-26. PubMed ID: 22877848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A common sense approach to radiotherapy planning of glioblastoma multiforme situated in the temporal lobe.
    Bokstein F; Kovner F; Blumenthal DT; Ram Z; Templehoff H; Kanner AA; Corn BW
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):900-4. PubMed ID: 18407432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.